Begins Coverage on DBV Technologies (NASDAQ:DBVT) started coverage on shares of DBV Technologies (NASDAQ:DBVTFree Report) in a research note published on Saturday. The firm issued a hold rating on the stock.

Separately, HC Wainwright cut their target price on DBV Technologies from $20.00 to $10.00 and set a buy rating on the stock in a research report on Wednesday, May 8th.

Get Our Latest Stock Analysis on DBVT

DBV Technologies Price Performance

DBV Technologies stock opened at $1.00 on Friday. The firm has a market capitalization of $96.49 million, a price-to-earnings ratio of -1.19 and a beta of 0.69. The company has a fifty day simple moving average of $1.20 and a 200-day simple moving average of $1.52. DBV Technologies has a 52-week low of $0.84 and a 52-week high of $4.52.

DBV Technologies (NASDAQ:DBVTGet Free Report) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.16. The business had revenue of $1.41 million during the quarter, compared to the consensus estimate of $3.20 million. DBV Technologies had a negative net margin of 530.89% and a negative return on equity of 56.76%. On average, research analysts anticipate that DBV Technologies will post -1.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Cowen AND Company LLC purchased a new stake in DBV Technologies during the 4th quarter worth $49,000. Optiver Holding B.V. increased its holdings in DBV Technologies by 595.2% during the 3rd quarter. Optiver Holding B.V. now owns 274,874 shares of the company’s stock worth $374,000 after purchasing an additional 235,337 shares during the last quarter. Finally, Yiheng Capital Management L.P. boosted its stake in shares of DBV Technologies by 6.2% during the 1st quarter. Yiheng Capital Management L.P. now owns 5,568,909 shares of the company’s stock valued at $4,172,000 after buying an additional 327,345 shares during the last quarter. 71.74% of the stock is currently owned by institutional investors and hedge funds.

About DBV Technologies

(Get Free Report)

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

Read More

Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with's FREE daily email newsletter.